ArticlemedRxiv : the preprint server for health sciences2026
Linking Cognitive Variability and Alzheimers Disease Biomarkers by Neurocognitive Status.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
16 authors.
Funding
Abstract
Objective: To assess intra-individual cognitive variability (IICV) in relation to Alzheimer's Disease (AD) biomarkers. Methods: The sample included 879 adults from the National Alzheimer's Coordinating Center, aged 50 and above with a complete neuropsychological evaluation and AD biomarker data available (64% cognitively intact; 36% cognitively impaired). We conducted a series of moderated regression models where AD biomarkers, neurocognitive status, and their interaction effects predicted IICV. IICV measures included demographically adjusted normed scores for the intraindividual standard deviation (iSD) and coefficient of variance (CoV). AD biomarkers included cerebrospinal fluid (CSF) measures of Aβ Results: Increased AD biomarker burden was associated with increased IICV among cognitively impaired individuals (correlational strength ranging from .206 to .391 for iSD and from .149 to .460 for CoV) but not among the cognitively intact group (correlational strength ranging from .008 to .085 for iSD and from .016 to .085 for CoV). The pattern of results held even after controlling for demographic factors and was comparable in magnitude to the association between AD biomarkers and mean cognitive performance. Conclusions: Increases in measures of amyloid, soluble tau, and neurodegeneration are associated with increased IICV among cognitively impaired older adults. The findings underscore the potential of IICV as a sensitive outcome measure in the AD clinical disease phase. Future studies should replicate findings longitudinally and in more diverse samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.